Connect Biopharma Holdings Limited (CNTB)

NASDAQ: CNTB · IEX Real-Time Price · USD
1.42
-0.03 (-2.07%)
Aug 16, 2022 11:14 AM EDT - Market open
-2.07%
Market Cap 78.12M
Revenue (ttm) n/a
Net Income (ttm) -204.19M
Shares Out 55.02M
EPS (ttm) -3.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 90,245
Open 1.54
Previous Close 1.45
Day's Range 1.36 - 1.54
52-Week Range 0.56 - 26.41
Beta n/a
Analysts Buy
Price Target 7.27 (+412.0%)
Earnings Date n/a

About CNTB

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingos... [Read more...]

Industry Biotechnology
IPO Date Mar 19, 2021
Employees 108
Stock Exchange NASDAQ
Ticker Symbol CNTB
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for CNTB stock is "Buy." The 12-month stock price forecast is 7.27, which is an increase of 411.97% from the latest price.

Price Target
$7.27
(411.97% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022

— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled —

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

SAN DIEGO, CA and TAICANG, SUZHOU, China, June 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”) announced on June 16, 2022, Connect B...

All You Need to Know About Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Rating Upgrade to Buy

Connect Biopharma Holdings Limited Sponsored ADR (CNTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Connect Biopharma to Participate at the Jefferies Healthcare Conference

SAN DIEGO, CA and TAICANG, SUZHOU, China, June 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceu...

Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Derm...

SAN DIEGO, CA and TAICANG, China, May 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical com...

Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage Study

Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced topline results at 12 weeks from its Phase 2 trial for CBP-307 (CBP-307CN002) for ulcerative colitis. CBP-307 0.2 mg demonstrated a numerical ...

Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe U...

SAN DIEGO, CA and TAICANG, China, May 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical com...

Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update

- Global Phase 3 Trial of CBP-201 in Moderate-to-Severe Atopic Dermatitis Expected to Commence in H2 2022 - - Topline P ha se 2 CBP-307 Results in Mo d er a te-to- S evere Ulcerative Colitis Expected to...

Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical Officer

CMO appointment to propel Connect through clinical milestones across solid pipeline of inflammatory disease therapies in development

Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference

SAN DIEGO and TAICANG, China, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical compan...

Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference

—Data provides detailed results, with achievement of both primary and key secondary end points and demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo

Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares

Key takeaways: Loss-making Connect Biopharma says Phase 3 clinical trials of its CBP-201 drug for atopic dermatitis will begin in second half of this year

Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with ...

—Phase 2b trial previously reported achievement of both primary and key secondary end points, demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo—

Connect Biopharma to Host Conference Call on January 5 at 8:30 AM ET to Review Detailed Data from the Global Phase 2b...

SAN DIEGO and TAICANG, China, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical compan...

Connect Biopharma Expands Executive Leadership Team with Hire of Chief Financial Officer

SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceu...

Why Connect Biopharma Stock Is Crashing Today

Investors wanted more details from the company's latest clinical results.

Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis

SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceu...

Connect Biopharma's Mid-Stage Atopic Dermatitis Trial Meets Primary Endpoint

Connect Biopharma Holdings Limited (NASDAQ: CNTB) has reported topline results from the Phase 2 trial of CBP-201 administered subcutaneously (SC) to adult patients with moderate-to-severe atopic dermati...

Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients wit...

Primary endpoint met with all three CBP-201 arms achieving significant improvements

Connect Biopharma to Participate at Upcoming Conferences

SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceu...

Connect Biopharma to Participate at the Jefferies Virtual China Biotech Summit

SAN DIEGO, CA and TAICANG, SUZHOU, China, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceu...

Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results

- On Track to Report CBP-201 Phase 2B Top-Line Data Evaluating Moderate-to-Severe Atopic Dermatitis (AD) in Q4 of 2021 -

Connect Biopharma to Host First Half 2021 Financial Results Conference Call on September 1, 2021

SAN DIEGO and TAICANG, SUZHOU, China, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutica...

Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member

TAICANG, SUZHOU, China and SAN DIEGO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutica...

Connect Biopharma to Participate at the Jefferies Virtual Healthcare Conference

SAN DIEGO and TAICANG, SUZHOU, China, May 26, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical...